Improving outcomes for New Zealand men with prostate cancer.

J. Nacey,B. Delahunt,S. Mark
2014-02-14
Abstract:Early diagnosis of prostate cancer is largely driven by the use of prostate-specific antigen (PSA) testing. Following its introduction in the 1980s, PSA created a revolution, resulting in a definite stage migration from high-grade, high-risk cancer toward low-grade low-risk, disease. 3,4 It is a powerful tool for measuring a man’s response to prostate cancer treatment and assessing disease progression. Nevertheless, this remains a controversial test because an abnormal result may not predict prostate cancer and is likely to lead to prostate biopsy.
What problem does this paper attempt to address?